Xylazine Test Strips

The District of Columbia has initiated a procurement opportunity for Xylazine Test Strips, a critical public health and safety contract targeting substance abuse detection and monitoring. The contract (ID: 6821e106cf83c7842305c595) was officially posted on February 4, 2025, with proposals due by February 18, 2025. This procurement appears focused on acquiring specialized testing equipment to detect the presence of xylazine, a potent veterinary tranquilizer increasingly found in illicit drug supplies. Potential vendors will need to demonstrate technical capabilities in producing reliable, rapid-response test strips that can accurately identify xylazine in various substance samples. The procurement likely requires vendors to provide comprehensive documentation, including product specifications, testing methodologies, sensitivity and specificity data, and compliance with relevant public health standards. Potential respondents should be prepared to submit detailed technical proposals demonstrating their product's effectiveness in harm reduction and public health monitoring contexts.

While specific set-aside designations are not explicitly detailed in the provided information, government contracts typically prioritize minority-owned, women-owned, and disadvantaged business enterprises. The contract may have specific local preferences or requirements for District of Columbia-based vendors. Given the specialized nature of the procurement, respondents will likely need demonstrated expertise in medical diagnostic technologies, substance abuse detection, and public health interventions. The potential award value is not specified, but similar public health procurement contracts often range from $50,000 to $500,000, depending on the volume and sophistication of test strips required. Vendors should be prepared to provide comprehensive pricing structures, including unit costs, potential volume discounts, and long-term contract pricing models. Additionally, respondents may need to demonstrate capacity for rapid production, quality control processes, and the ability to meet potential emergency or expanded public health testing requirements.